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Introduction. We report a two centre experience with a depopulated ureteric xenograft (SGVG 100, CryoLife Inc., GA,
USA) for femoropopliteal revascularization in 12 patients with chronic critical limb ischemia.
Report. Between 7 days and 18 months after implantation, 10 of 12 patients (1 lost to follow-up) had the graft explanted
due to aneurysmal enlargement. At 5 years, only one graft was still patent and showed moderate signs of enlargement.
Conclusion. The SGVG 100 is not a safe conduit for femoropopliteal bypass surgery.
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Chronic critical limb ischemia is a condition character-
ized by chronic ischemic pain at-rest, ulcers, or gan-
grene in one or both legs attributable to peripheral
arterial occlusive disease (PAOD).
Limb preservation by means of revascularization is
cost-effective, leads to a better quality of life for most
patients and is associated with lower peri-operative
morbidity and mortality than amputation. We report
the experience of two referral centres in Northern
Italy with the prosthetic graft SGVG-100 (CryoLife
Inc., GA, USA).
Report
Between February and December 2001, twelve pa-
tients with advanced PAOD, category 3e6 as defined
by Rutherford et al.,1 were scheduled to receive ei-
ther an above knee or a below knee femoropopliteal
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with chronic critical limb ischemia (rest pain or ul-
ceration) and absent or unsuitable saphenous vein.
Pre-operative angiography was routinely per-
formed on all patients. Any stenosis that would limit
the inflow was corrected either at the time of the diag-
nostic angiography or during the surgical procedure.
In 3 cases, an on-table angioplasty of one of the calf
vessels was necessary to increase the run-off. All anas-
tomoses were routinely carried out using 6/0 polypro-
pylene suture.
All patients were followed up at 3-monthly inter-
vals, with Echo-color Doppler examination to check
both the patency and size of the conduit.
Results
There were no surgical deaths. Satisfactory haemosta-
sis of the anastomoses was achieved easily, also in
part due to the distinctive texture of the conduit. All
operations were straightforward.
One graft occluded a few days after implantation
and the patient had to be brought back to theatre
twice within the following 3 days. On all occasions,
an on-table angiogram failed to reveal any technicalrved.
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peared to be normal. After the third thrombectomy,
the patient was started on long-term anticoagulation.
The graft was still patent 6 months later, but subse-
quently the patient was lost to follow-up.
Two patients required emergency surgery for
severe haemorrhage due to graft disruption within
2 weeks after the initial operation. The first patient
suffered from aneurysmal enlargement of the whole
length of the xenograft and underwent a second pro-
cedure 15 days after implantation (Figs. 1 and 2). The
second patient presented with massive haemorrhage
for ruptured mid-graft aneurysm 7 days post opera-
tively. On both occasions, the xenograft was explanted
and replaced with an 8 mm PTFE conduit. We
stopped using the xenograft after this second event
occurred. All patients were contacted for tighter fol-
low-up. Within 18 months, all grafts had significantly
enlarged from baseline, and 10 out of 12 patients had
the conduit explanted due to progressive enlargement
(maximum diameter 51 mm).
The pathologist’s report from the explanted xeno-
graft showed extensive areas of granulation tissue
around the rupture site, rich in lymphocytes and
eosinophils. About half the circumference of the graft
was involved in inflammatory response. The section
with most disruption had a thicker wall with the
opposite side being much thinner. All staining for
bacteria and fungi in these sections were negative.
Discussion
The ideal bypass conduit is the greater saphenous
vein, but other conduits include the lesser saphe-
nous veins, the arm veins or a prosthetic conduit.
Despite many efforts from industry, the reported
Fig. 1. Surgical demonstration of the site of rupture.primary and secondary patency rate for autologus
saphenous vein grafts are significantly better than
for synthetic grafts at 4 years.2 Campbell and Field
first used a bovine ureter with good long-term
patency and low rates of infection and aneurysmal
evolution.3 The SGVG-100 is a user-friendly, non-
glutaraldehyde fixed, acellular collagen and elastin
matrix conduit capable of autologous cell repopula-
tion by the recipient. Although it has proven to be
resistant to infection, we do not believe that it
represents a safe choice for extensive distal bypass.
In our view, one hypothesis that could explain the
acute graft enlargement is a hyper-acute immunologic
response. A chronic inflammatory process could
justify the aneuriysmal evolution in all other cases,
as recently proposed by Sharp and colleagues.4 An-
other hypothesis to explain the chronic enlargement
could focus on the factory process to remove cells.
This may have disrupted the connective and elastic
fibres, leading to a progressive enlargement due to
a reduced compliance of the conduit wall to the arte-
rial pressure. This hypothesis also is supported by the
good results for the SGVG-100 when is used in dif-
ferent vascular beds with particular haemodynamic
characteristics.5 Although the SGVG-100 might be
useful for short reconstructions, we do not advise its
use for above knee or a below knee femoropopliteal
bypass.
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